other material
confidence high
sentiment positive
materiality 0.75
Matinas BioPharma oral LNC docetaxel shows tumor reduction comparable to IV in melanoma model
Matinas BioPharma Holdings, Inc.
- Oral LNC docetaxel reduced tumor volume 63% (high dose) and 57% (low dose) vs 68% for IV docetaxel at Day 14.
- No systemic toxicity observed over 10 days; body weight and hematologic parameters stable.
- Company plans further studies in other tumor models and longer treatment regimens to confirm safety.
- Also plans to evaluate LNC formulations for small oligonucleotide anti-tumor activity.